The World Health Organization identifies headache disorders (“symptomatic at least once within the last year”) among the most common disorders of the nervous system, affecting 50% of adults worldwide. Thirty percent of those affected reported having had a migraine in the last year. Moreover, 1.7 – 4% of adults worldwide experience headaches 15 or more days per month. If on 8 of those 15 days, features of migraine headaches are also present, and if this persists for 3 months, then one would be diagnosed as having chronic migraines. Chronic migraines affect 1% of the population, or about 75,000,000 people across the globe.
It is estimated that about 36,000,000 Americans suffer from migraines, but only 1 in 3 people discuss this with a physician. Depression and anxiety often accompany migraines, so suffering extends beyond physical pain. The 2015 Global Burden of Disease study identified migraine as the third cause of disability in adults under the age of fifty. Migraines leave sufferers unable to function as usual, interfering with their physical and mental health, productivity, quality of life, and financial security.
Treatments for migraines include but are not limited to pain-relieving medications, preventative medications, acupuncture, biofeedback, yoga , meditation, and cognitive behavioral therapy (CBT). Botox has even been found as efficacious in the treatment of migraines, and the FDA approves the use of Botox to treat migraines in adults who are age 18 and older.
Despite the number of effective treatments available, still some people experience refractory migraines, or migraines that do not respond to standard treatments. Recent small studies (such as this one ) suggest the efficacy of ketamine infusion therapy in the treatment of chronic migraines. Ketamine is an antagonist of NMDA-subtype glutamate receptors, which are thought to play a role in pain transmission. Subjects with refractory migraines who were given ketamine infusion therapy reported a significant decrease in pain on the VAS scale.
Once you contact us and/or we receive a referral from your headache care provider you will be contacted by our team. You will receive a NMKW initial screening packet to complete and return for our physicians to determine if you are a candidate for ketamine therapy. If so, you will be contacted to schedule your clinical interview and potential infusion date. NMKW offers ketamine infusions in a quiet,spa-like environment with safety and precision provided by a board-certified anesthesiologist. Wear comfortable clothing as you simply recline in a chair during your treatments. You have the option to rest quietly or listen to soft music. Plan to be here for about 2 hours when you scheduled for an infusion. Infusions take anywhere from 45-60 minutes with a 30 minute after-infusion observance period. We have special rates with nearby hotels, contact us for more information if you wish to stay in the Gaylord area during your treatment. Please contact us if you have questions or need more information.
Our goal at NMKW is to offer adjunct therapy to the treatment you are already providing your patient. We want to collaborate with you to provide ketamine therapy for your patients with chronic refractory migraines. Our screening protocols include medical history assessment, pain and migraine disability assessments, and depression/addiction screening if indicated. As part of this screening process, clarification of past treatments and responses will be obtained. Once clinical appropriateness is determined, ketamine infusion therapy will involve a sub-anesthetic and sub-dissociative dose given slowly, monitored by a board certified anesthesiologist, built around best practices. To initiate treatment for your patient we will need patient contact information as well as pertinent medical records. To refer your patient to NMKW contact us at 989-350-9155.
Ketamine, a derivative of phencyclidine, is an anesthetic drug that was developed in 1962 and has been widely used in a variety of settings. Ketamine acts as an antagonist of the N-methyl-D-aspartate (NMDA) receptor and targets glutamate, which is an excitatory amino acid neurotransmitter. Ketamine has been used to induce and maintain general anesthesia for more than 30years and is on the World Health Organizations List of Essential Medicines. Ketamine is FDA-approved as an anesthetic and has a remarkably safe track record in clinical settings.
The duration of symptomatic relief patients experience following ketamine therapy varies greatly. After finishing the first series of infusions we will follow your length of relief. Patients who have return of symptoms may receive maintenance or "tune up" infusions to extend their response. When patients do experience such relief, it may be the first time in years that they have felt healthy and "normal".
Ketamine is most commonly known as an anesthetic used in surgical procedures. You may know of ketamine as a rave drug used recreationally since the 1980's. The utilization of ketamine to treat migraine headaches is not yet FDA-approved, as the approval process can take years due to funding, research and time required.
When ketamine is administered in a controlled medical setting by a properly trained and licensed clinician using established methods, monitoring, and protocols it is very safe. When used recreationally ketamine use can have very serious adverse effects.
Most research shows some possible short-lived side effects of Ketamine including headache, anxiety, dissociation, nausea, and dizziness. These can be commonly treated on site.
Yes, Ketamine is legal. Ketamine treatment is an intravenous infusion performed in a specially-equipped medical office under the direction of a physician.
No, Ketamine treatment is NOT covered by insurance yet. NMKW accepts payments via money order, cash,or credit card.